Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT

NCT06198517 NA RECRUITING

This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.

Details

Lead sponsor	Yi Zhang
Phase	NA
Status	RECRUITING
Enrolment	266
Start date	Thu Mar 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Moxibustion
• Hematopoietic Stem Cell Transplantation
• Hemorrhagic Cystitis
• Prevention

Interventions

• Moxibustion
• Symptomatic treatment

Countries

China